MDGL
$443.18
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor bet...
Recent News
Is Madrigal Pharmaceuticals (MDGL) Pricing Look Interesting After Long Term Share Price Surge?
If you are wondering whether Madrigal Pharmaceuticals' current share price reflects its underlying worth, you are not alone. The stock has attracted attention from investors trying to work out if the recent run justifies the valuation. The shares last closed at US$432.78, with returns of 1.6% over 7 days, a 9.4% decline over 30 days, a 27.1% decline year to date, but a 29.0% return over 1 year, 76.9% over 3 years and 271.3% over 5 years. Recent news flow around Madrigal has focused on its...
2 Under-the-Radar Stocks to Buy and Hold
These biotechs are slowly making a name for themselves.
What Makes Madrigal Pharma (MDGL) One of the Shorted Biotech Stocks to Buy
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 20, Bank of America Securities lowered the price target on Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) from $570 to $529, resulting in upside potential above 22%. The firm maintained its Neutral rating on the stock. Following […]
Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the stocks with explosive growth potential. On February 19, Madrigal Pharmaceuticals announced the earnings report for 2025, which was driven by the successful launch of Rezdiffra, the first approved treatment for MASH. Full-year net sales reached $958.4 million, with Q4 revenue alone hitting $321.1 million, more than tripling […]
Why Madrigal Pharmaceuticals (MDGL) Is Down 9.7% After Rezdiffra’s Near US$1 Billion Debut Year
Madrigal Pharmaceuticals reported fourth-quarter 2025 net loss of US$58.58 million and a full-year 2025 net loss of US$288.28 million, while its newly launched MASH therapy Rezdiffra generated close to US$1 billion in net sales in its first full year on the market. Alongside these results, Madrigal highlighted plans to expand Rezdiffra’s use through the F4c trial and advance more than 10 combination and next‑generation pipeline programs, aiming to build a broader MASH treatment...